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ABSTRACT: Complex [RuCp(PPh3)2(HdmoPTA)](OSO2CF3)2 (2) 
was synthesized and characterized by elemental analysis, IR and 
NMR spectroscopy. Its crystal structure was also determined by 
single-crystal X-ray diffraction. The complex showed a more 
potent antiproliferative activity than cisplatin against a repre-
sentative panel of human cancer cells. 
The development of effective anticancer drugs is mandatory for 
medicinal chemists. Cancer is one of the plagues of our time that 
has not a general and totally effective cure. The earliest studies by 
B. Rosenberg in 1965 on the antiproliferative activity of cisplatin 
and its FDA-approval as a chemotherapeutic agent in 1979 led to 
this compound to be one of the most clinical useful anticancer 
drugs.1 Nevertheless its value, cisplatin is not active against all 
cancer forms and displays several undesirable side effects such as 
large toxicity.2 Many attempts are being focused to obtain new 
valuable anticancer drugs, effective on a large classes of cancer 
varieties, less toxic and better tolerated by the human body. Some 
compounds containing metals different to Pt have showed com-
parable anticancer activity than cisplatin but with fewer side 
effects, ruthenium complexes being one of the most currently 
interesting alternative.3 Regarding platinum compounds rutheni-
um complexes exhibit lower systemic toxicity and specific accu-
mulation in cancer cells.3,6 The early experiments (1980s) with 
fac-[Cl3(NH3)3Ru], cis-[Cl2(NH3)4Ru]Cl (CCR) and (ImH)trans-
[(Im)2Cl4Ru] (ICR) showed that these compounds are active 
agents against the cervix cancer cell line HeLa with less toxicity 
than cisplatin.4 Since these initial findings, new anticancer ruthe-
nium-based therapeutic agents such as NAMI-A, KP1019, 












In the past, we have been engaged actively in the synthesis of 
arene-ruthenium complexes [RuCpX(L)(L´)]n+ (X = Cl; L PPh3; L´ 
= PTA, mPTA) (PTA = 1,3,5-triaza-7-phosphaadamantane; mPTA 
= N-methyl-PTA) (Figure 2), which showed good water solubility 
and active cytotoxic properties particularly on cisplatin resistant 
cells.7 Their antiproliferative activities were related to ligands 
bonded to the metal, which modify the electronic properties of 
the complexes but also their partition coefficient (Log P). The 
outcome of those studies pointed out that the same basic struc-
ture with new PTA derivatives (Figure 2) could provide more 
active anticancer agents. 
  
Figure 1. Some known ruthenium complexes with significant anticancer 





















With this aim, the ruthenium complex 
[RuClCp(PPh3)(HdmoPTA)](OSO2CF3) (1), containing the new 
PTA derivative 3,7-H-3,7-dimethyl-1,3,7-triaza-5-
phosphabicyclo[3.3.1]nonane (HdmoPTA), was obtained.8 This 
ligand is able to be solubilized in water and organic solvents and 
its solubility could be modified easily by deprotonation.  
Complex 1 was identified as an antiproliferative compound 
against a panel of representative human solid tumor cell lines 
with GI50 values in the range 1.5-2.6 µM (Table 1, vide infra). Nev-
ertheless, it is important to stress that the antiproliferative prop-
erties of this complex were found to be clearly different to those 
of their parent complexes.9 
Substitution of the proton in HdmoPTA by a metal provided 
bis-heterometal complexes [RuClCp(PPh3)-µ-dmoPTA-
1kP:2k2N,N’-MCl2](M = Co, Ni, Zn),10a which showed similar anti-
proliferative activity than 1.9 This fact suggested that the biologi-
cal activity of these complexes could implicate the exchange of 
the Cl bonded to the Ru, as for Pt complexes has been observed.4 
To investigate this possibility the new {CpRu} parent complex 
[RuCp(PPh3)2(HdmoPTA)](OSO2CF3)2 (2), which does not con-
tain Cl bonded to the metal, was synthesized (see ESI†) by the 
reaction of [RuClCp(PPh3)2] first with Ag(OSO2CF3) and then 
with dmPTA(OSO2CF3)2 (Scheme 1) (dmPTA = N,N´-dimethyl-











Complex 2 is soluble in organic solvents such as chloroform, 
acetone, methanol, DMSO and mostly insoluble in water 
(S25,H2O(mg/cm
3): 0.2). The complex remains unaltered in DMSO 
and DMSO/H2O solutions under air for more than 2 h both at 
room temperature and 38 °C. Its 1H NMR (CDCl3) displays a char-
acteristic h5-Cp singlet at 4.90 ppm, which is shifted to low field 
with respect to its correspondent in 1 (4.56 ppm) in acetone-d6. 
The PPh3 signals (30 H) arise at typical aromatic range. The re-
maining signals belong to the HdmoPTA group, two contiguous 
broad singlets are due to both NCH3 groups at 2.35 ppm and 2.36 
ppm (6 H), which resemble those of the NCH3 groups in 1 (2.49 
ppm).8 Finally, the multiplet at 1.25 ppm (1 H) corresponds to the 
hydrogen shared between both NCH3 atoms. This suspicion was 
confirmed by a 1H,1H-2D COSY NMR experiment that showed 
how this signal is coupled with NCH2NCH3 and PCH2NCH3 
groups (Figure S1, ESI†). The 31P{1H} NMR in CDCl3 shows a dou-
blet at 38.44 ppm (2P) and a triplet at -13.94 ppm (1P) that only 
could be assigned respectively to two PPh3 and one HdmoPTA 
coordinated by the P atom despite of those chemical shifts are 
quite different to those in complex 1 (46.13 ppm; -1.80 ppm) in 
acetone-d6.  
The crystal structure of 2 was determined by single-crystal X-
ray diffraction and is showed in Figure 3 (selected crystallograph-
ic parameters, distances and angles are display in Table S1, ESI†). 
The crystallographic study confirmed that the coordination 
sphere of the Ru is a distorted pseudo-octahedron constituted by 
a h5-Cp, two PPh3 and a HdmoPTA bonded by the P atom. The 
Cp ring is essentially planar (the larger separation from the over-
all Cp plane is 0.0089 Å (C84)), being the distance to the metal 
(Ru-Cpcent.= 1.886 Å) similar to those found in parent Cp-piano-
stool complexes.8,10 The angle between the Cp plane and the 
plane defined by P1-Ru1-P3 (47.6°) and P2-Ru1-P3 (46.8°) are 
smaller than that in 1 ( 55.3°) while the angle P1-Ru1-P2 is found 
to be 103.3(4)°, which is near to that observed in similar complex-
es [RuCpX(PPh3)2] (X = CN, 103.6(1)°; CNHCN, 102.5(1)°).11 The 
NCH3···NCH3 distance of 2.800 Å is somewhat larger than that for 1 
(dN1P···N3P = 2.702 Å) and the torsion angles for the cationic unit 
HdmoPTA (C75-N73-C73-P3 = -57.3° and C76-N71-C71-P3 = 51.6°) 
somewhat shorter than those in 1 (C5P-N1P-C3P-P2 = -54.5° and 



















Furthermore, the O2T is located more than 3 Å from C62, well 
outside of normal H-bonding distance but at 2.814(6) Å from N71, 
bond length that supports the H-bond interaction N71-H71···O2T 
(dH71···O2T= 2.103(4) Å). Likewise, the crystal packing diagram is 
strengthened by another weak intermolecular interaction (C81-
H81···F21 = 3.433(3) Å) and the C-H/p interactions12 between the 
aromatic centroid and the adjacent phenyl-C-H groups (centroid-
to-C-H distances from 3.183(5) to 4.039(5) Å, Figure 4). 
  
Figure 2. A careful selection of ligands, metal centre, and reaction conditions can 
confer control over the topology of the piano-stool complexes [RuCpX(L)(L´)]n+ (X 
= Cl; L = PPh3; L´= PTA, mPTA; dmPTA; HdmoPTA) allowing modulation of the 
activity against human tumour cells. 
Scheme 1. Synthesis of [RuCp(PPh3)2(HdmoPTA)](OSO2CF3)2 (2) 
Figure 3. A perspective drawing of 2 with atom numbering. For the sake 
of clarity, the dashed lines N73···H71 (2.178(4) Å) and O2T···H62 (2.578(4) 















The antiproliferative activity of 2 was studied in a panel of rep-
resentative human solid tumour cell lines.13 Thus, cells were ex-
posed to the compound for 48 h and the results expressed as GI50 
are given in Table 1. Overall, the GI50 values of 2 against all cell 
lines were in the range 0.17-0.29 µM, which are significantly lower 
than those for the reference anticancer drug cisplatin and com-
plex 1. Significant differences between antiproliferative activity of 
2 and cisplatin were observed for T-47D (ca. 70:1) and WiDr (> 
100:1) cells, which are more cisplatin resistant.9  
It is important to point out that the GI50 values of 2 are larger 
than those for 1.9 To the best of our knowledge the antiprolifera-
tive activity of 2 against human solid tumour cell lines is among 
the largest known.14 
The main structural difference between 1 and 2 is the presence 
of one or two PPh3 groups, respectively. The enhancement of the 
biological activity due to the addition of PPh3 ligands has been 
reported for other ruthenium complexes.15 This result is con-
sistent with the reported findings for 1 and 2, and with our previ-
ous observations of the parent PTA and HPTA complexes 
RuCp(DMSO-κS)(PTA)2](OSO2CF3), [RuCp(DMSO-
κS)(HPTA)2]Cl3·2H2O and [RuClCp(HPTA)2]Cl2·2H2O,10b which 
were tested against HeLa, SW1573, T-47D and WiDr cells, result-
ing inactive (GI50 > 100 μM) in all cell lines (unpublished results). 
Noteworthy, the presence of PPh3 groups is not always enough 
for ensuring an antiproliferative effect. Solubility of the complex-
es plays also a crucial role. For instance, {CpRu} precursor 
[RuClCp(PPh3)2] is insoluble under the NCI protocol require-


















Next, we examined cell cycle phase distribution by flow cytome-
try13 to determine whether cell growth inhibition caused by com-
pound 2 involved cell cycle changes (Figure 5, Table S6, ESI†). 
Contrary to cisplatin, which induces the accumulation in S-phase 
of A549, SW1573 and WiDr cells, we found that ruthenium com-
plex 2 produced the accumulation at G1 phase of the cell cycle. 
However, in HeLa cells, cisplatin is known to induce accumula-
tion at G1 phase.16 Interestingly, compound 2 produced an in-
crease of the G2/M compartment in HeLa. These results clearly 
indicate that the mechanism of action of the new compound 


























H. Liu and P. Sadler17 have shown that the insertion of a coor-
dinated aromatic ligand able to intercalate into DNA provides 
some metal complexes with a dual mode of binding, that is, inter-
calation between the DNA bases and metal coordination to a 
DNA base. Ru-arene complexes with such a dual mode of binding 
exhibit stronger cytotoxicity toward cancer cells than the non-
intercalating counterparts.18  
Cell cycle experiments together with our previous finding for 
complex 1,9 allow us to discard DNA as the main biological target 
for compound 2. It has been described that ruthenium com-
pounds might directly interfere with proteins.14b At present, this 
extent has not been confirmed for complex 2.  
Another interesting point to study is the role of the positively 
charged complex, which might be essential to force interaction 
with the negatively charged cell membrane. The geometries of 
complexes 1 and 2 were modelled by DFT19,20 (see ESI†) with the 
aim of obtaining information of how it changes from those in 
crystal and to know how the charges are distributed in molecules, 
which could justify their different antiproliferative activity. The 
modelled structures of both complexes retain the disposition of 
the ligands around the metal as in the crystal. The HOMO-
LUMO energy gap is very similar in both complexes (3.840 eV for 
1, 3.858 eV for 2), being the HOMO/LUMO energies of 1 the 
higher (1: HOMO = -10.267 eV, LUMO = -6.427 eV; 2: HOMO = -
7.333 eV, LUMO = -3.475 eV). For both complexes the largest 
bond distance differences respecting those in crystal structures 
were found for Ru-P bonds: +8.7% for Ru1-P1 in 1 and +10.5% for 
Ru1-P2 in 2. 
  









































b Values are given in μM and are means of at least three experiments 
(±standard deviation). 
Table 1. GI50 values of complexes 1,a 2 and cisplatin against human solid 
tumor cells lines.b 
Figure 4. C-H/π interactions in 2: dcentroid-to-C32-H32 = 3.183(5); dcentroid-to-C34-H34 = 
4.039(5) and dcentroid-to-C42-H42 = 3.470(5). 
Figure 5. Histogram of untreated cells (C) and cells treated (drug dose in 
μM) for 24 h with cisplatin (CDDP) and complex 2. Cells were exposed to 
cisplatin at 10 µM (A549, HeLa and SW1573) or 20 µM (WiDr), and to 
complex 2 at 0.5 µM. 
 
The charge distribution on the phenyl rings of 1 and 2 do not 
differ significantly. Therefore, the electronic distribution in both 
complexes is similar and could not justify the large antiprolifera-
tive activity differences between them. Nevertheless, the separa-
tion (from 3.951 to 3.871 Å) between both almost parallel (4.73°, 
Figure S4, ESI†) phenyl rings C21-C26 and C61-C66 (Figure 4), 
which could be the responsible of the exceptional antiprolifera-
tive activity of 2.21 Nonetheless, other possible mechanisms have 
been identified to justify the biological activity of ruthenium 
complexes14 and therefore, further studies outside the scope of 
this work will be necessary to depict the mechanism of action of 
2.  
In conclusion, complex 2 displays a high antiproliferative activi-
ty largely bigger than most of the known platinum drugs and 
ruthenium complexes. Experimental and theoretical studies are 
in progress to determine the specific mechanism of action of 
complex 2 against cancer cells. The synthesis of parent ruthenium 
complexes containing the ligand HdmoPTA and its derivatives is 
also in progress as well as the study of their biological activity. 
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The complex [RuCp(PPh3)2(HdmoPTA)](OSO2CF3)2 showed more potent antiproliferative activity 
than cisplatin against a representative panel of human cancer cells. 
